Month: September 2024

Fairfax India to Acquire 65% of Global Aluminium Private Limited

Written by Customer Service on September 6, 2024. Posted in Mergers And Acquisitions.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this news release are expressed in U.S. dollars, except as otherwise noted). TORONTO, Sept. 06, 2024 (GLOBE NEWSWIRE) — Fairfax India Holdings Corporation (“Fairfax India” or the “Company”) (TSX: FIH.U) announces that, through its wholly-owned subsidiary, it has entered into an agreement to invest INR 6,955 million (approximately $83 million at current exchange rates) for a 65.0% interest in Global Aluminium Private Limited (“Global Aluminium”). The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2024. Global Aluminium is the third-largest aluminum extrusions manufacturer in India with in-house capabilities to produce anodized and powder-coated aluminum products....

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on September 6, 2024. Posted in Public Companies.

NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 111,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024...

Elutia Celebrates First Year

Written by Customer Service on September 6, 2024. Posted in Public Companies.

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of “Humanizing Medicine so Patients can Thrive without Compromise.” The following day, the company began trading on Nasdaq under the new ticker symbol “ELUT.” In its first year as Elutia, the company achieved several significant milestones and saw impressive organic growth, including:Focused operations on our proprietary drug-eluting biomatrix technology through the divestiture and...

Pheton Holdings Ltd Announces Closing of Initial Public Offering

Written by Customer Service on September 6, 2024. Posted in Public Companies.

BEIJING, China, Sept. 06, 2024 (GLOBE NEWSWIRE) — Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced the closing of its initial public offering (the “Offering”) of 2,250,000 Class A ordinary shares at a public offering price of $4.00 per share, for total gross proceeds of $9 million, before deducting underwriting discounts and other related expenses. The Company has granted the underwriters an option, exercisable within 45 days from the closing date of the Offering, to purchase up to an additional 337,500 Class A ordinary shares at the initial public offering price, less underwriting discounts to cover over-allotments, if any. The Company’s Class A ordinary shares began trading on the...

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Written by Customer Service on September 6, 2024. Posted in Public Companies.

SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion,...

Vertex to Present at Goldman Sachs Conference

Written by Customer Service on September 6, 2024. Posted in Public Companies.

KING OF PRUSSIA, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Monday, September 9, 2024 at 9:30 AM Pacific Time. Live webcasts and replays of both presentations will be available on Vertex’s investor relations website at ir.vertex.com. About Vertex Vertex is a leading global provider of indirect tax software and solutions. The company’s mission is to deliver the most trusted tax technology enabling global businesses to transact, comply and grow with confidence. Vertex provides solutions that can be tailored to specific industries for major lines of indirect...

Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024

Written by Customer Service on September 6, 2024. Posted in Public Companies.

Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced plans to host a conference call and webcast to report data for RLY-2608 600mg BID + fulvestrant in the ongoing ReDiscover trial in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer and next steps on Monday, September 9, 2024, at 8:00 a.m. ET. Conference Call Information Registration and dial-in for the conference call and webcast may be accessed...

Lifecore Biomedical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on September 6, 2024. Posted in Public Companies.

CHASKA, Minn., Sept. 06, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Lifecore has granted a restricted stock unit (“RSU”) award with respect to 262,500 shares of its common stock and a performance stock unit (“PSU”) award for up to 750,000 shares of its common stock to Ryan D. Lake, Lifecore’s newly hired chief financial officer. The RSU award and PSU award were granted September 3, 2024, pursuant to the Company’s previously announced employment agreement with Mr. Lake, and as a material inducement to Mr. Lake joining Lifecore as chief financial officer. The RSU award and PSU award were approved by Lifecore’s compensation committee and were granted as inducement equity awards...

Codexis Announces New Employment Inducement Grants

Written by Customer Service on September 6, 2024. Posted in Public Companies.

REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis’ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company’s 2024 Inducement Plan. The stock options have an exercise price equal to the closing price per share of Codexis’ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent...

Foresight Receives Nasdaq Notification Regarding Minimum Bid Requirements

Written by Customer Service on September 6, 2024. Posted in Public Companies.

Ness Ziona, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems, announced today that on September 3, 2024, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its American Depositary Shares (“ADSs”) was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until March 3, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must meet or exceed $1.00...

Month: September 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals